LUND, SWEDEN--(Marketwire - March 28, 2013) - The number of shares and votes in Active
Biotech has changed as a result of the
directed new issue to Investor as previously announced.
Today, the last trading day of the month, there are in total 74,923,582
and votes in Active Biotech.
Lund, March 28, 2013
Active Biotech AB (publ)
Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company
focus on autoimmune/inflammatory diseases and cancer. Projects in pivotal
are laquinimod, an orally administered small molecule with
immunomodulatory properties for the treatment of multiple sclerosis,
for prostate cancer and ANYARA primarily for the treatment of renal cell
In addition, laquinimod is in Phase II development for Crohn's and
company also has one additional project in clinical development, the
administered compound 57-57 for Systemic Sclerosis. Please
www.activebiotech.com for more information.
Active Biotech AB (Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 46 19 20 00
Fax: +46 46 19 11 00
Active Biotech is required under the Financial Instruments Trading Act to
the information in this press release public. The information was submitted
publication at 08:30 a.m. CET on March 28, 2013.
Number of shares and votes in Active Biotech:
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Active Biotech via Thomson Reuters ONE